Effects of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Men
Novel Evaluations of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Men Compared to Age Group-Matched Transgender Women and Cisgender Adults
1 other identifier
observational
16
1 country
1
Brief Summary
This study will examine markers of vascular endothelial function (vascular health) and metabolic profiles in older versus younger transgender men (people who were assigned female at birth but whose gender identity is male). Data will also be compared to those from age group-matched transgender women and cisgender women and men.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 17, 2020
CompletedFirst Posted
Study publicly available on registry
January 23, 2020
CompletedStudy Start
First participant enrolled
January 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedSeptember 19, 2024
September 1, 2024
3.9 years
January 17, 2020
September 13, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluation of endothelial function (flow-mediated dilation (FMD)
Brachial artery flow-mediated dilation (FMD), as measured by ultrasound.
Baseline
Secondary Outcomes (25)
Evaluation of carotid artery compliance
Baseline
Evaluation of carotid artery beta stiffness index
Baseline
Carotid artery intimal-medial thickness
Baseline
Evaluation of oxidant burden: oxidized LDL
Baseline
Evaluation of oxidant burden: nitrotyrosine
Baseline
- +20 more secondary outcomes
Study Arms (2)
Older transgender men
This cohort will consist of transgender men aged 50-75 years old who have taken testosterone for at least one year.
Younger transgender men
This cohort will consist of transgender men aged 18-40 years old who have taken testosterone for at least one year.
Interventions
Eligibility Criteria
Transgender men from the Denver metropolitan area and/or who utilize health care at University of Colorado Hospital.
You may qualify if:
- Aged 18-40 years old or 50-75 years old
- Identify as a transgender woman
- Have taken testosterone for at least one year
- Currently taking testosterone parenterally (injections) or transdermally (patches or gels)
You may not qualify if:
- Don't identify as a transgender man
- Not currently taking testosterone
- Have been on testosterone for less than one year
- History of hysterectomy/oophorectomy
- Current tobacco smoker
- Current illicit drug use
- History of prior or active estrogen-dependent neoplasms
- Acute liver or gallbladder disease
- Venous thromboembolism
- Hypertriglyceridemia \>500 mg/dL
- Fasted plasma glucose \>7.0 mmol/L or previously treated diabetes
- Resting blood pressure \>140/90 mmHg
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Colorado
Aurora, Colorado, 80045, United States
Biospecimen
Endothelial cells
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sean Iwamoto, MD
University of Colorado, Denver
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 17, 2020
First Posted
January 23, 2020
Study Start
January 29, 2020
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
September 19, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share